AU2019303777B2 - Salt of LSD1 inhibitor and a polymorph thereof - Google Patents

Salt of LSD1 inhibitor and a polymorph thereof Download PDF

Info

Publication number
AU2019303777B2
AU2019303777B2 AU2019303777A AU2019303777A AU2019303777B2 AU 2019303777 B2 AU2019303777 B2 AU 2019303777B2 AU 2019303777 A AU2019303777 A AU 2019303777A AU 2019303777 A AU2019303777 A AU 2019303777A AU 2019303777 B2 AU2019303777 B2 AU 2019303777B2
Authority
AU
Australia
Prior art keywords
crystal form
compound iii
compound
pattern
present disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019303777A
Other languages
English (en)
Other versions
AU2019303777A1 (en
Inventor
Shuhui Chen
Jianjun Sun
Lingyun Wu
Lele ZHAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Original Assignee
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd filed Critical CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Publication of AU2019303777A1 publication Critical patent/AU2019303777A1/en
Application granted granted Critical
Publication of AU2019303777B2 publication Critical patent/AU2019303777B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019303777A 2018-07-20 2019-07-19 Salt of LSD1 inhibitor and a polymorph thereof Active AU2019303777B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810804068 2018-07-20
CN201810804068.3 2018-07-20
PCT/CN2019/096842 WO2020015745A1 (zh) 2018-07-20 2019-07-19 一种lsd1抑制剂的盐及其晶型

Publications (2)

Publication Number Publication Date
AU2019303777A1 AU2019303777A1 (en) 2021-02-11
AU2019303777B2 true AU2019303777B2 (en) 2023-01-19

Family

ID=69163657

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019303777A Active AU2019303777B2 (en) 2018-07-20 2019-07-19 Salt of LSD1 inhibitor and a polymorph thereof

Country Status (8)

Country Link
US (1) US12024494B2 (enExample)
EP (1) EP3825309B1 (enExample)
JP (1) JP7358466B2 (enExample)
KR (1) KR102778948B1 (enExample)
CN (1) CN112424175B (enExample)
AU (1) AU2019303777B2 (enExample)
CA (1) CA3106484C (enExample)
WO (1) WO2020015745A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021228146A1 (zh) * 2020-05-12 2021-11-18 石药集团中奇制药技术（石家庄）有限公司 一种lsd1抑制剂的用途
KR20230167102A (ko) 2021-04-08 2023-12-07 오리존 지노믹스 에스.에이. 골수성 암 치료를 위한 lsd1 억제제의 조합물
JP2025516647A (ja) 2022-05-09 2025-05-30 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｌｓｄ１阻害薬を用いる悪性末梢神経鞘腫（ｍｐｎｓｔ）の治療法
WO2023217784A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合
CN116069221A (zh) * 2022-12-27 2023-05-05 北京字跳网络技术有限公司 媒体内容的展示方法、装置、电子设备和存储介质
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018137644A1 (zh) * 2017-01-24 2018-08-02 南京明德新药研发股份有限公司 Lsd1抑制剂及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705675B1 (fr) * 1993-05-27 1996-05-03 Smithkline Beecham Labo Pharma Nouveaux composés, leur procédé de préparation et leur utilisation en tant que médicaments.
WO2010084160A1 (en) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
HUE030938T2 (en) * 2010-04-19 2017-06-28 Oryzon Genomics Sa Lysine-specific demethylase-1 inhibitors and their use
MX341732B (es) * 2010-07-29 2016-08-30 Oryzon Genomics S A * Inhibidores de la demetilasa lsd1 basados en arilciclopropilamina y sus usos médicos.
SG193241A1 (en) * 2011-03-25 2013-10-30 Glaxosmithkline Ip No 2 Ltd Cyclopropylamines as lsd1 inhibitors
CN110402244B (zh) * 2015-08-12 2023-02-03 因赛特公司 Lsd1抑制剂的盐
SG10202010414QA (en) 2016-04-22 2020-11-27 Incyte Corp Formulations of an lsd1 inhibitor
CA3022561A1 (en) * 2016-05-09 2017-11-16 Sridharan Rajagopal Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018137644A1 (zh) * 2017-01-24 2018-08-02 南京明德新药研发股份有限公司 Lsd1抑制剂及其制备方法和应用

Also Published As

Publication number Publication date
EP3825309B1 (en) 2023-09-06
CA3106484A1 (en) 2020-01-23
KR102778948B1 (ko) 2025-03-07
WO2020015745A1 (zh) 2020-01-23
CN112424175B (zh) 2022-10-28
EP3825309A1 (en) 2021-05-26
KR20210034058A (ko) 2021-03-29
AU2019303777A1 (en) 2021-02-11
JP2021530565A (ja) 2021-11-11
CA3106484C (en) 2024-06-25
CN112424175A (zh) 2021-02-26
US20210317096A1 (en) 2021-10-14
JP7358466B2 (ja) 2023-10-10
US12024494B2 (en) 2024-07-02
EP3825309A4 (en) 2022-03-23

Similar Documents

Publication Publication Date Title
AU2019303777B2 (en) Salt of LSD1 inhibitor and a polymorph thereof
RU2663663C2 (ru) Соль омекамтива мекарбила и способ ее получения
RU2633694C2 (ru) Дейтерированный фениламинопиримидин и фармацевтическая композиция, содержащая такое соединение
RU2769050C1 (ru) Кристаллическая форма и солевая форма соединения пиридоимидазола и соответствующий способ получения
JP2022530812A (ja) Ｗｅｅ１阻害剤化合物の結晶形及びその応用
EP3395817A1 (en) Pyrido[1,2-a]pyrimidone analog, crystal form thereof, intermediate thereof and preparation method therefor
CN114929701B (zh) 一种pde3/pde4双重抑制剂的结晶及其应用
TW202408510A (zh) Ｃｄｋ抑制劑及其磷酸鹽的多晶型、其製備方法、包含其的醫藥組合物及其用途
WO2023174400A1 (zh) 一种取代的氨基六元氮杂环类化合物的盐及其晶型、制备方法和应用
WO2004111024A1 (ja) チアジアゾリン誘導体
RU2536685C2 (ru) Фармацевтически приемлемые соли тимодепрессина и способ их получения
RU2794977C2 (ru) Соль ингибитора lsd1 и её полиморфная форма
EP2551257A1 (en) Co-crystals of agomelatine with co-crystal-formers
US20250197408A1 (en) Crystalline forms and salts of a pi3k inhibitor and methods of making and methods of use thereof
CN114728973A (zh) 一种核蛋白抑制剂的晶型及其应用
CN110167554B (zh) 一种具有抗癌作用的化合物及其制备方法和应用
EP4438600A1 (en) Compound used as kinase inhibitor and use thereof
CN117843638A (zh) 基于rsl3诱导gpx4蛋白降解的双功能分子化合物的制备与应用
HK40038512B (en) Salt of lsd1 inhibitor and a polymorph thereof
HK40038512A (en) Salt of lsd1 inhibitor and a polymorph thereof
CN111484497B (zh) 咪唑并[1,5-a]吡嗪类衍生物的可药用盐、晶型及其制备方法
US12391653B2 (en) Salt form and crystal form of mutant IDH1 inhibitor and preparation method therefor
EP4089086B1 (en) Crystal form of pyrrolidinyl urea derivative and application thereof
EP3950694A1 (en) Salt form and crystal form of a2a receptor antagonist and preparation method therefor
HK40072576B (zh) 用作激酶抑制剂的化合物及其应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)